Table 1. Characteristics of patients with myeloid malignancies and the RANBP2-ALK fusion gene.

Characteristic	This case	Maesako et al.⁵	Lim et al.¹⁰	Rottgers et al.¹¹ Patient 3	Patient 4	Patient 6
Diagnosis	AML (M4)	AML	AML (M4)	MDS or JMML	AML (M4)	JMML
Karyotype	46,XX,inv(2)(p23q13) [20] (at diagnosis) 45,XX,inv(2)(p23q13), -7 [5] (relapse)	46, XX, inv(2)(p23q13) [1]/, 45, idem, -7 [8]/,46, idem, -7, +mar [1]	45,XX,inv(2)(p23q13),-7 [20]	45,XY,inv(2) (p23q13),-7 [5]	46,XY,inv(2)(p23q13) [3]/, 45,idem,-7 [8]	45,XY,t(2;2) (p23;q11~13),-7
Age at diagnosis	2.8 Years	75 Years	31.4 Years	8 Years	16.3 Years	3.5 Years
Initial therapy regimen	VP-16, Ara-C, IDA	Ara-C, DNR, AZA (every 4 weeks)	Ara-C, DNR	Ara-C, DNR, VP-16	Ara-C, DNR, VP-16	Ara-C, DNR, VP-16
Response to initial therapy	Relapse 6 months after diagnosis, during consolidation therapy	Relapse after eight cycles of AZA	Induction failure	Recurrence of blasts on day 26	Early relapse after 6 months	Low persistent blast cells ranging between 2 and 6% during the next 4 months
Salvage therapy regimen	IDA+FLAG, AZA, Crizotinib	Crizotinib	Ara-C, MIT, VP-16	—	liposomal DNR, FLU, Ara-C	—
Response to crizotinib therapy	Molecular CR after 51 days crizotinib	Blasts disappeared from peripheral blood after 71 days crizotinib: blasts reappeared on day 135	—	—	—	—
HCT	HCT from HLA5/8 matched mother	—	MUD HCT	—	MFD HCT	MUD HCT
Clinical outcome	Alive 1 year after HCT	No data	Relapse 3 months after HCT; death 7 months after relapse	Early death due to infection	Alive 6 years after HCT	Alive 8 years after HCT

Abbreviations: AML, acute myeloid leukemia; Ara-C, cytarabine; AZA, azacitidine; DNR, daunorubicin; FLAG, fluradabine, cytarabine and granulocyte colony-stimulating factor; FLU, fludarabine; HCT, hematopoietic cell transplantation; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndromes; MFD, matched family donor; MIT, mitoxantrone; MUD, matched unrelated donor; VP-16, etoposide.